{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:22:20Z","timestamp":1784575340409,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K0237504"],"award-info":[{"award-number":["24K0237504"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KOSE Cosmetology Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiepileptic drugs must be continually used to control seizures in pregnant people with epilepsy. Lacosamide (LCM) and perampanel (PER) are third-generation antiepileptic drugs that were introduced to clinical practice in 2008 and 2012, respectively. LCM and PER are increasingly being prescribed. However, little information is available regarding the safety or placental transfer of LCM and PER during pregnancy. We investigated the placental permeability of LCM in vivo and the effects of LCM and PER on efflux transporters in human placental cells in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical umbilical cord and maternal plasma samples were collected from a woman who had been receiving a regular oral regimen of 100\u00a0mg LCM twice daily. The LCM concentrations in the samples were quantified using ultra-high-performance liquid chromatography\/tandem mass spectrometry. Accumulation assays were conducted using in vitro syncytiotrophoblast models to determine the effects of LCM and PER on the functions of efflux transporters, including breast cancer resistance protein (BCRP\/\n                      <jats:italic>ABCG2<\/jats:italic>\n                      ), multidrug resistance proteins (MRPs\/\n                      <jats:italic>ABCCs<\/jats:italic>\n                      ), and P-glycoprotein (P-gp\/\n                      <jats:italic>ABCB1<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The LCM concentrations in the maternal plasma and umbilical cord plasma samples were 4.02\u00a0\u00b5g\/mL (predelivery trough level) and 3.22\u00a0\u00b5g\/mL (3.5\u00a0h after last dose), respectively. The LCM concentration in the umbilical cord plasma was near the lower end of the maternal therapeutic range, and the fetal-to-maternal plasma concentration ratio likely remained below 1.0. Therapeutic concentrations of LCM and PER did not increase the accumulation of fluorescent substrates of the efflux transporters in the in vitro assays. In contrast, high LCM doses increased the accumulation of BODIPY\u2122 FL prazosin, a BCRP substrate, whereas PER did not affect the accumulation of any substrate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LCM was transferred to the fetus at concentrations close to the lower end of the therapeutic range, suggesting that fetal plasma levels did not exceed the maternal levels. High LCM concentrations inhibited BCRP function in vitro, whereas PER did not inhibit major placental efflux transporters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00537-z","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:35:40Z","timestamp":1769247340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel"],"prefix":"10.1186","volume":"12","author":[{"given":"Ayami","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Furugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Umazume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinata","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.seizure.2022.03.017","volume":"98","author":"R Shawahna","year":"2022","unstructured":"Shawahna R, Zaid L. Concentrations of Antiseizure medications in breast milk of lactating women with epilepsy: A systematic review with qualitative synthesis. Seizure. 2022;98:57\u201370. https:\/\/doi.org\/10.1016\/j.seizure.2022.03.017.","journal-title":"Seizure"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","volume":"10","author":"T Tomson","year":"2011","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609\u201317. https:\/\/doi.org\/10.1016\/S1474-4422(11)70107-7.","journal-title":"Lancet Neurol"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. Lancet Neurol. 2013;12:244\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(12)70323-X.","journal-title":"Lancet Neurol"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaneurol.2019.4443","volume":"77","author":"AK Birnbaum","year":"2020","unstructured":"Birnbaum AK, Meador KJ, Karanam A, Brown C, May RC, Gerard EE, et al. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol. 2020;77:441\u201350. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4443.","journal-title":"JAMA Neurol"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","volume":"110","author":"MA Rogawski","year":"2015","unstructured":"Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current Understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189\u2013205. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.11.021.","journal-title":"Epilepsy Res"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","volume":"16","author":"M Baulac","year":"2017","unstructured":"Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: A phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16:43\u201354. https:\/\/doi.org\/10.1016\/S1474-4422(16)30292-7.","journal-title":"Lancet Neurol"},{"key":"537_CR7","doi-asserted-by":"publisher","unstructured":"Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl. 2013;1973\u20138. https:\/\/doi.org\/10.1111\/ane.12098.","DOI":"10.1111\/ane.12098"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.seizure.2022.04.007","volume":"98","author":"D Kikuchi","year":"2022","unstructured":"Kikuchi D, Obara T, Miura R, Suzuki N, Josaka R, Tokunaga M, et al. Trends in the prescription of anti-seizure medicines for pregnant women outpatients with epilepsy during 2016\u20132020 in Japan. Seizure. 2022;98:101\u20134. https:\/\/doi.org\/10.1016\/j.seizure.2022.04.007.","journal-title":"Seizure"},{"key":"537_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0169-409x(02)00174-6","volume":"55","author":"AM Young","year":"2003","unstructured":"Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev. 2003;55:125\u201332. https:\/\/doi.org\/10.1016\/s0169-409x(02)00174-6.","journal-title":"Adv Drug Deliv Rev"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40264-015-0299-3","volume":"38","author":"AN Daud","year":"2015","unstructured":"Daud AN, Bergman JE, Bakker MK, Wang H, Kerstjens-Frederikse WS, de Walle HE, Groen H, Bos JH, Hak E, Wilffert B. P-Glycoprotein-Mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: A Case-Reference study. Drug Saf. 2015;38:651\u20139. https:\/\/doi.org\/10.1007\/s40264-015-0299-3.","journal-title":"Drug Saf"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/bcp.14191","volume":"86","author":"M Ellfolk","year":"2020","unstructured":"Ellfolk M, Tornio A, Niemi M, Leinonen MK, Lahesmaa-Korpinen AM, Malm H. Placental transporter-mediated drug interactions and offspring congenital anomalies. Br J Clin Pharmacol. 2020;86:868\u201379. https:\/\/doi.org\/10.1111\/bcp.14191.","journal-title":"Br J Clin Pharmacol"},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/humupd\/dmv049","volume":"22","author":"E Bloise","year":"2016","unstructured":"Bloise E, Ortiga-Carvalho TM, Reis FM, Lye SJ, Gibb W, Matthews SG. ATP-binding cassette transporters in reproduction: a new frontier. Hum Reprod Update. 2016;22:164\u201381. https:\/\/doi.org\/10.1093\/humupd\/dmv049.","journal-title":"Hum Reprod Update"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/epi.12158","volume":"54","author":"C Zhang","year":"2013","unstructured":"Zhang C, Chanteux H, Zuo Z, Kwan P, Baum L. Potential role for human P-glycoprotein in the transport of lacosamide. Epilepsia. 2013;54:1154\u201360. https:\/\/doi.org\/10.1111\/epi.12158.","journal-title":"Epilepsia"},{"key":"537_CR14","doi-asserted-by":"publisher","first-page":"120161","DOI":"10.1016\/j.ijpharm.2020.120161","volume":"593","author":"J Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves J, Silva S, Gouveia F, Bicker J, Falc\u00e3o A, Alves G, et al. A combo-strategy to improve brain delivery of antiepileptic drugs: focus on BCRP and intranasal administration. Int J Pharm. 2021;593:120161. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120161.","journal-title":"Int J Pharm"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.stem.2017.11.004","volume":"22","author":"H Okae","year":"2018","unstructured":"Okae H, Toh H, Sato T, Hiura H, Takahashi S, Shirane K, et al. Derivation of human trophoblast stem cells. Cell Stem Cell. 2018;22:50\u2013e636. https:\/\/doi.org\/10.1016\/j.stem.2017.11.004.","journal-title":"Cell Stem Cell"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.placenta.2025.03.021","volume":"165","author":"R Sawada","year":"2025","unstructured":"Sawada R, Furugen A, Ueda A, Nishimura A, Umazume T, Narumi K, et al. Analysis of drug transporter expression in syncytiotrophoblast derived from human placental stem cells: expression and function of efflux transporters. Placenta. 2025;165:23\u201332. https:\/\/doi.org\/10.1016\/j.placenta.2025.03.021.","journal-title":"Placenta"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40780-023-00295-w","volume":"9","author":"A Furugen","year":"2023","unstructured":"Furugen A, Nishimura A, Umazume T, Ishikawa H, Narumi K, Kobayashi M. Simple and validated method to quantify lacosamide in human breast milk and plasma using UPLC\/MS\/MS and its application to estimate drug transfer into breast milk. J Pharm Health Care Sci. 2023;9:26. https:\/\/doi.org\/10.1186\/s40780-023-00295-w.","journal-title":"J Pharm Health Care Sci"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"116611","DOI":"10.1016\/j.taap.2023.116611","volume":"474","author":"N Ohyama","year":"2023","unstructured":"Ohyama N, Furugen A, Sawada R, Aoyagi R, Nishimura A, Umazume T, et al. Effects of valproic acid on syncytialization in human placental trophoblast cell lines. Toxicol Appl Pharmacol. 2023;474:116611. https:\/\/doi.org\/10.1016\/j.taap.2023.116611.","journal-title":"Toxicol Appl Pharmacol"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/fcp.12971","volume":"38","author":"M Cercos","year":"2024","unstructured":"Cercos M, Seqat I, Facile A, Vial T, Auffret M. Lacosamide use during breastfeeding: A case report and a literature review. Fundam Clin Pharmacol. 2024;38:575\u20138. https:\/\/doi.org\/10.1111\/fcp.12971.","journal-title":"Fundam Clin Pharmacol"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13318-019-00601-8","volume":"45","author":"L Schultz","year":"2020","unstructured":"Schultz L, Mahmoud SH. Is therapeutic drug monitoring of lacosamide needed in patients with seizures and epilepsy? Eur J Drug Metab Pharmacokinet. 2020;45:315\u201349. https:\/\/doi.org\/10.1007\/s13318-019-00601-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"537_CR21","unstructured":"Japanese Society of Neurology. Epilepsy practice guidelines 2018. 2018. http:\/\/neurology-jp.org\/guidelinem\/tenkan_2018.html. Accessed 12 Nov 2021."},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0037-1600991","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:e1. https:\/\/doi.org\/10.1055\/s-0037-1600991.","journal-title":"Pharmacopsychiatry"},{"key":"537_CR23","unstructured":"Japan Co UCB. Ltd. Vimpat\u00ae (lacosamide) Interview Form. https:\/\/hcp.ucbcares.jp\/pdf\/vimpat\/tablet100mg\/interview-form. Accessed 30 Jun, 2025."},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1111\/epi.17395","volume":"63","author":"E Berman","year":"2022","unstructured":"Berman E, Kohn E, Berkovitch M, Kovo M, Eyal S. Lacosamide effects on placental carriers of essential compounds in comparison with valproate: studies in perfused human placentas. Epilepsia. 2022;63:2949\u201357. https:\/\/doi.org\/10.1111\/epi.17395.","journal-title":"Epilepsia"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2015.01.015","volume":"93","author":"K R\u00f6mermann","year":"2015","unstructured":"R\u00f6mermann K, Helmer R, L\u00f6scher W. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Neuropharmacology. 2015;93:7\u201314. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.01.015.","journal-title":"Neuropharmacology"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN. The clinical Pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56:12\u201327. https:\/\/doi.org\/10.1111\/epi.12865.","journal-title":"Epilepsia"},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1476-5381.2009.00336.x","volume":"158","author":"K V\u00e4h\u00e4kangas","year":"2009","unstructured":"V\u00e4h\u00e4kangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158:665\u201378. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00336.x.","journal-title":"Br J Pharmacol"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.yebeh.2021.108253","volume":"123","author":"D Zutshi","year":"2021","unstructured":"Zutshi D, Millis SR, Basha MM, Daimee MA, Srinivas M. Lacosamide serum concentrations during pregnancy. Epilepsy Behav. 2021;123:108253. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108253.","journal-title":"Epilepsy Behav"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reprotox.2015.07.068","volume":"57","author":"P Ylikotila","year":"2015","unstructured":"Ylikotila P, Ketola RA, Timonen S, Malm H, Ruuskanen JO. Early pregnancy cerebral venous thrombosis and status epilepticus treated with Levetiracetam and lacosamide throughout pregnancy. Reprod Toxicol. 2015;57:204\u20136. https:\/\/doi.org\/10.1016\/j.reprotox.2015.07.068.","journal-title":"Reprod Toxicol"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1248\/yakushi.22-00044","volume":"142","author":"S Kitamura","year":"2022","unstructured":"Kitamura S, Nishimura A, Takekuma Y, Saito Y, Umazume T, Sugawara M. Case report on a woman with epilepsy who took lacosamide during pregnancy and gave birth to a healthy infant. Yakugaku Zasshi. 2022;142:1031\u20135. https:\/\/doi.org\/10.1248\/yakushi.22-00044.","journal-title":"Yakugaku Zasshi"},{"key":"537_CR31","doi-asserted-by":"publisher","first-page":"100490","DOI":"10.1016\/j.ebr.2021.100490","volume":"16","author":"AM Alicino","year":"2021","unstructured":"Alicino AM, Falcicchio G, Boero G, Santarcangelo G, Francavilla T, Trojano M, et al. Perampanel during pregnancy: description of four cases. Epilepsy Behav Rep. 2021;16:100490. https:\/\/doi.org\/10.1016\/j.ebr.2021.100490.","journal-title":"Epilepsy Behav Rep"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00537-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:05:00Z","timestamp":1781629500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00537-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00537-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Hokkaido University Hospital (020\u20130139). Written informed consent was obtained from the participant. This study was performed in accordance with the Declaration of Helsinki and the ethical guidelines for clinical research in Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ayako Furugen is affiliated with a laboratory supported by Sato Pharmaceutical Co., Ltd.; however, this laboratory was not involved in this study. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}